The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?

The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.

The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.

A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.